Addition of chemotherapy to nivolumab after PD-1 inhibitor failure as bridge to allogeneic stem cell transplantation in classical Hodgkin’s lymphoma: report on three cases and literature review

1. Moskowitz, AJ, Perales, MA, Kewalramani, T, et al. Outcomes for patients who fail high dose chemoradiotherapy and autologous stem cell rescue for relapsed and primary refractory Hodgkin lymphoma. Br J Haematol 2009; 146: 158–163.
Google Scholar | Crossref | Medline2. Piñana, JL, Sanz, J, Esquirol, A, et al. Umbilical cord blood transplantation in adults with advanced Hodgkin’s disease: high incidence of post-transplant lymphoproliferative disease. Eur J Haematol 2016; 96: 128–135.
Google Scholar | Crossref | Medline3. Sureda, A, Stavrik, SG, Boumendil, A, et al. Changes in patients population and characteristics of hematopoietic stem cell transplantation for relapsed/refractory Hodgkin lymphoma: an analysis of the Lymphoma Working Party of the EBMT. Bone Marrow Transplant 2020; 55: 2170–2179.
Google Scholar | Crossref | Medline4. Chen, R, Gopal, AK, Smith, SE, et al. Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma. Blood 2016; 128: 1562–1566.
Google Scholar | Crossref | Medline | ISI5. Armand, P, Engert, A, Younes, A, et al. Nivolumab for relapsed/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II CheckMate 205 trial. J Clin Oncol 2018; 36: 1428–1439.
Google Scholar | Crossref | Medline6. Chen, R, Zinzani, PL, Lee, HJ, et al. Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087. Blood 2019; 134: 1144–1153.
Google Scholar | Crossref | Medline7. Rossi, C, Gilhodes, J, Maerevoet, M, et al. Efficacy of chemotherapy or chemo-anti-PD-1 combination after failed anti-PD-1 therapy for relapsed and refractory Hodgkin lymphoma: a series from Lysa centers. Am J Hematol. Epub ahead of print 8 June 2018. DOI: 10-1002/ajh.25154.
Google Scholar | Crossref8. Lepik, KV, Mikhailova, NB, Kondakova, EV, et al. A study of safety and efficacy of nivolumab and bendamustine (NB) in patients with relapsed/refractory Hodgkin lymphoma after nivolumab monotherapy failure. Hemasphere 2020; 4: e401.
Google Scholar | Crossref | Medline9. Baues, C, Trommer-Nestler, M, Jablonska, K, et al. Short review of potential synergies of immune checkpoint inhibition and radiotherapy with a focus on Hodgkin lymphoma: radio-immunotherapy opens new doors. Immunotherapy 2017; 9: 423–433.
Google Scholar | Crossref | Medline10. Herrera, AF, Chen, RW, Palmer, J, et al. PET-adapted nivolumab or nivolumab plus ICE as first salvage therapy in relapsed or refractory Hodgkin lymphoma. Blood 2019; 134(Supplement_1): 239.
Google Scholar | Crossref | Medline11. Nie, J, Wang, C, Liu, Y, et al. Addition of low-dose decitabine to anti-PD-1 antibody camrelizumab in relapsed/refractory classical Hodgkin lymphoma. J Clin Oncol 2019; 37: 1479–1489.
Google Scholar | Crossref | Medline12. Herrera, AF, Chen, L, Popplewell, LL, et al. Preliminary results from a phase I trial of pembrolizumab plus vorinostat in patients with relapsed or refractory diffuse large B-cell lymphoma, follicular lymphoma, and Hodgkin lymphoma. Blood 2019; 134(Supplement_1): 759.
Google Scholar | Crossref13. Ramchandren, R, Domingo-Domènech, E, Rueda, A, et al. Nivolumab for newly diagnosed advanced-stage classic Hodgkin lymphoma: safety and efficacy in the phase II Checkmate 205 Study. J Clin Oncol 2019; 37: 1997–2007.
Google Scholar | Crossref | Medline14. Bröckelmann, PJ, Goergen, H, Keller, U, et al. Efficacy of nivolumab and AVD in early-stage unfavourable classic Hodgkin lymphoma: the randomized phase 2 German Hodgkin Study Group NIVAHL Trial. JAMA Oncol 2020; 6: 1–9.
Google Scholar | Crossref15. Allen, PB, Savas, H, Evens, AM, et al. Pembrolizumab followed by AVD in untreated early unfavourable stage classical Hodgkin lymphoma. Blood. Epub ahead of print 29 September 2020. DOI: 10.1182/blood.20200007400.
Google Scholar | Crossref16. Carreau, NA, Pail, O, Armand, P, et al. Checkpoint blockade treatment may sensitize Hodgkin lymphoma to subsequent therapy. Oncologist 2020; 25: 878–885.
Google Scholar17. Galluzzi, L, Senovilla, L, Zitvogel, L, et al. The secret ally: immunostimulation by anticancer drugs. Nat Rev Drug Discov 2012; 11: 215–233.
Google Scholar | Crossref | Medline18. Galluzzi, L, Zitvogel, L, Kroemer, G. Immunological mechanisms underneath the efficacy of cancer therapy. Cancer Immunol Res 2016; 4: 895–902.
Google Scholar | Crossref | Medline | ISI19. Cubas, R, Moskalenko, M, Cheung, J, et al. Chemotherapy combines effectively with anti-PD-L1 treatment and can augment antitumor responses. J Immunol 2018; 201: 2273–2286.
Google Scholar | Crossref | Medline20. Herbaux, C, Gauthier, J, Brice, P, et al. Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin lymphoma. Blood 2017; 129: 2471–2478.
Google Scholar | Crossref | Medline21. Martínez, C, Carpio, C, Heras, I, et al. Potential survival benefit for patients receiving allogeneic hematopoietic stem cell transplantation after nivolumab therapy for relapsed/refractory Hodgkin lymphoma: real-life experience in Spain. Biol Blood Marrow Transplant 2020; 26: 1534–1542.
Google Scholar | Crossref | Medline22. Merryman, RW, Castagna, L, Giordano, L, et al. Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma. Leukemia. Epub ahead of print 3 March 2021. DOI: 10.1038/s41375-021-01193-6.
Google Scholar | Crossref | Medline23. Ijaz, A, Khan, AY, Malik, SU, et al. Significant risk of graft-versus-host-disease with exposure to checkpoint inhibitors before and after allogeneic transplantation. Biol Blood Marrow Transplant 2019; 25: 94–99.
Google Scholar | Crossref | Medline24. Dada, R, Usman, B. Allogeneic hematopoietic stem cell transplantation in r/r Hodgkin lymphoma after treatment with checkpoint inhibitors: feasibility and safety. Eur J Haematol 2019; 102: 150–156.
Google Scholar | Crossref | Medline25. Montoro, J, Piñana, JL, Hernández-Boluda, JC, et al. Uniform graft-versus-host disease prophylaxis with posttransplant cyclophosphamide, sirolimus, and mycophenolate mofetil following hematopoietic stem cell transplantation from haploidentical, matched sibling and unrelated donors. Bone Marrow Transplant 2020; 55: 2147–2159.
Google Scholar | Crossref | Medline

留言 (0)

沒有登入
gif